Application of Musella lasiocarpa extract in the preparation of products for reducing uric acid

Abstract

The present invention relates to the technical field of plant extracts, and particularly to the application of extracts of Musella lasiocarpa in the preparation of products for reducing uric acid. Research shows that the ethanol extracts of the flowers and flower buds of Musella lasiocarpa of the present invention (i.e., the crude extracts of Musella lasiocarpa), refined components (RC1-RC6) and C1-C6 compounds all have strong inhibitory activities against xanthine oxidase, thereby effectively reducing the uric acid level, having the advantages of good uric acid reducing effect and small side effects, and can be used in the preparation of products for reducing uric acid.

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to the application of extracts of Musella lasiocarpa in the preparation of products for reducing uric acid. Background Art

[0002] Uric acid is the final product of purine metabolism, and its generation in the body mainly stems from endogenous purine synthesis and exogenous purine intake (such as purine-rich foods like animal offal, seafood, certain beans, etc.). Under normal circumstances, the human body excretes about two-thirds of uric acid through the kidneys and about one-third through the intestines to maintain the blood uric acid concentration within a relatively stable range. However, when the activity of key enzymes in the purine metabolism process is abnormal, such as a decrease in the activity of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and an increase in the activity of phosphoribosyl pyrophosphate synthetase (PRPP), or when the kidney's excretion function of uric acid is impaired, it will lead to excessive production or reduced excretion of blood uric acid, thereby causing hyperuricemia.

[0003] With the changes in people's lifestyles, including factors such as high-purine diets (such as a large intake of meat, seafood, alcohol, etc.), reduced physical activity, an increasing obesity rate, and population aging, the prevalence of hyperuricemia has shown a significant upward trend. Long-term hyperuricemia can cause urate crystals to deposit in joints, kidneys, blood vessels and other parts, thereby triggering gouty arthritis, tophi, uric acid nephropathy, cardiovascular diseases (such as coronary heart disease, hypertension, atherosclerosis, etc.) and the deterioration of metabolic syndrome-related diseases.

[0004] The clinical manifestations of gout are diverse. During an acute attack, it usually presents as redness, swelling, heat, and pain in the joints. The pain is often extremely severe and usually occurs suddenly at night. The most commonly affected joint is the first metatarsophalangeal joint, followed by the ankle joint, knee joint, etc. If gout is not effectively controlled for a long time, it will lead to joint deformity, dysfunction, and even gouty nephropathy, seriously affecting the quality of life of patients and increasing the disability rate and mortality rate. Therefore, early intervention in the early stage when the uric acid level is not particularly high or in the early stage of hyperuricemia and effective control of uric acid can effectively prevent the occurrence of diseases such as hyperuricemia or gout. It has an important positive significance for the physical health, economic burden, and quality of life of patients, and is an important concept and strategy for modern medicine to prevent and treat diseases. Summary of the Invention

[0005] In view of this, the present invention provides an application of extracts of Musella lasiocarpa in the preparation of products for reducing uric acid.

[0006] The application of extracts of Musella lasiocarpa or at least one of the following C1-C6 compounds in the preparation of xanthine oxidase inhibitors:

[0007] Compound C1: 1,2',3',4',6'-penta-O-acetyl-3-O-(E)-p-coumaroyl sucrose;

[0008] Compound C2: 2',3',4',6'-tetra-O-acetyl-3-O-(E)-p-coumaroyl sucrose;

[0009] Compound C3: mumeose K;

[0010] Compound C4: daucosterol linoleate;

[0011] Compound C5: glycerol-1-eicosanoate-3-(4E,7E,10E-hexadecatrienoate);

[0012] Compound C6: 2-linolenoyl-rac-glycerol;

[0013] The compounds C1-C6 are extracted and separated from the Musella lasiocarpa extract;

[0014] The Musella lasiocarpa extract is an ethanol extract of Musella lasiocarpa flowers and buds, which contains at least one of the compounds C1-C6.

[0015] Studies have shown that the ethanol extracts of Musella lasiocarpa flowers and buds (i.e., the crude extract of Musella lasiocarpa and the refined components RC1-RC6) and the compounds C1-C6 of the present invention all have strong inhibitory activities against xanthine oxidase and can effectively reduce the uric acid level.

[0016] Xanthine oxidase (XOD) participates in the purine metabolism process, catalyzes the oxidative hydroxylation reactions of hypoxanthine and xanthine to generate uric acid (UA), and reduces oxygen at the flavin center to generate reactive oxygen species. Excessive XOD activity will lead to an increase in uric acid production, resulting in hyperuricemia and even gout. Therefore, XOD is an effective target for the treatment of gout and other diseases related to hyperuricemia. Existing research reports have shown that xanthine oxidase inhibitors are the main method for reducing the serum uric acid level in gout patients (see William B. White, MD, Gout, Xanthine Oxidase Inhibition, and Cardiovascular Outcomes). Among them, the mechanism of action of xanthine oxidase inhibitors is to inhibit the activity of xanthine oxidase, reduce the synthesis of uric acid, and lower the uric acid level, thereby treating diseases caused by hyperuric acid such as hyperuricemia and gout.

[0017] Based on this, the present invention also provides the use of the Musella lasiocarpa extract or at least one of the following compounds C1-C6 in the preparation of a product for reducing uric acid:

[0018] Compound C1: 1,2',3',4',6'-penta-O-acetyl-3-O-(E)-p-coumaroyl sucrose;

[0019] Compound C2: 2',3',4',6'-tetra-O-acetyl-3-O-(E)-p-coumaroyl sucrose;

[0020] Compound C3: mumeose K;

[0021] Compound C4: daucosterol linoleate;

[0022] Compound C5: glycerol-1-eicosanoate-3-(4E,7E,10E-hexadecatrienoate);

[0023] Compound C6: 2-linolenoyl-rac-glycerol;

[0024] The compounds C1 to C6 are extracted and separated from the Musella lasiocarpa extract;

[0025] The Musella lasiocarpa extract is an ethanol extract of Musella lasiocarpa flowers and flower buds, which contains at least one of the compounds C1 to C6.

[0026] In the present invention, the uric acid-lowering product is a health food or food with uric acid-lowering efficacy, or a drug for preventing and treating hyperuricemia-related diseases;

[0027] The hyperuricemia-related diseases include hyperuricemia and / or gout.

[0028] In some embodiments, the Musella lasiocarpa extract is a crude extract of Musella lasiocarpa, and the preparation method includes:

[0029] Take the flowers and flower buds of Musella lasiocarpa, extract them by cold soaking with 75% ethanol, and concentrate them under reduced pressure to dryness to obtain the crude extract of Musella lasiocarpa.

[0030] In some specific embodiments, the preparation method of the crude extract of Musella lasiocarpa includes:

[0031] Extract by cold soaking with 3 volumes of 75% ethanol / water 3 times, 24 hours each time, and concentrate the extract to dryness to obtain the crude extract of Musella lasiocarpa.

[0032] In some other embodiments, the Musella lasiocarpa extract is the refined components RC1 to RC6, where RC is the abbreviation of Refined component, and the RC1 to RC6 are prepared from the above-mentioned crude extract of Musella lasiocarpa by the following method: subject the crude extract of Musella lasiocarpa to an MCI column, and successively use H 2Gradient elution was performed with O, 20% methanol solution, 40% methanol solution, 60% methanol solution, 80% methanol solution, and 100% methanol aqueous solution. Each gradient was eluted with 3 column volumes to obtain the refined components RC1 - RC6 of Musella lasiocarpa respectively.

[0033] Specifically, RC1 is the fraction eluted with water after MCI chromatography separation;

[0034] RC2 is the fraction eluted with 20% methanol aqueous solution after MCI chromatography separation;

[0035] RC3 is the fraction eluted with 40% methanol aqueous solution after MCI chromatography separation;

[0036] RC4 is the fraction eluted with 60% methanol aqueous solution after MCI chromatography separation;

[0037] RC5 is the fraction eluted with 80% methanol aqueous solution after MCI chromatography separation;

[0038] RC6 is the fraction eluted with 100% methanol after MCI chromatography separation.

[0039] In the present invention, the compounds of C1 - C6 (C is the abbreviation of compound) are separated from the above-mentioned RC2, RC3, RC4, RC5, and RC6. The specific separation method is as follows:

[0040] The refined component RC2 was loaded onto a silica gel column and eluted with dichloromethane - methanol (volume ratio 9:1 - 8:2), petroleum ether - isopropanol (volume ratio 8:2 - 7:3), ethyl acetate: methanol 9.8:0.2 to separate C4.

[0041] The refined component RC4 was loaded onto a silica gel column and eluted with dichloromethane - methanol (volume ratio 9.8:0.2 - 8:2), dichloromethane - isopropanol (volume ratio 9.8:0.2 - 9:1), petroleum ether - isopropanol (volume ratio 8:2 - 6:4); then loaded onto a Sephdex column and eluted with methanol to separate C3.

[0042] The refined component RC5 was loaded onto a silica gel column and eluted with dichloromethane - acetone (volume ratio 9:1 - 8:2), dichloromethane - methanol (volume ratio 9:1), petroleum ether - acetone (volume ratio 8:2 - 7:3) to separate C1.

[0043] The refined component RC6 was loaded onto a silica gel column and eluted with dichloromethane - methanol (volume ratio 9.8:0.2 - 9:1), dichloromethane - acetone, petroleum ether - acetone (volume ratio 9:1 - 7:3), petroleum ether - ethyl acetate (volume ratio 9:1 - 8:2), then loaded onto a Sephdex column and eluted with dichloromethane - methanol (volume ratio 1:1). After multiple separations, the refined compounds C2, C5, and C6 were obtained.

[0044] Specifically, the name of C1 compound is 1,2',3',4',6'-O-pentaacetyl-3-O-trans-p-coumaroylsucrose, CAS No: 1392307-46-8, which is Mumeose D, and its Chinese name is 1',2',3',4',6'-penta-O-acetyl-3-O-(E)-p-coumaroylsucrose, and its structural formula is C 31 H 38 O 18 , and the specific structure is as follows:

[0045] .

[0046] Compound C2: 2',3',4',6'-tetra-O-acetyl-3-O-(E)-p-coumaroyl sucrose, CAS No: 1603815-30-0, Chinese name: 2',3',4',6'-tetra-O-acetyl-3-O-(E)-p-coumaroyl sucrose, and its structural formula is C 25 H 32 O 15 , and the specific structure is as follows:

[0047] .

[0048] Compound C3: mumeose K, CAS No: 2132384-01-9,

[0049] Structural formula: C 25 H 32 O 15 , and the specific structure is as follows:

[0050] .

[0051] Compound C4: daucosterol linoleate, CAS No: 79380-30-6,

[0052] Chinese name: daucosterol linoleate, 3-O-(6'-O-linoleoyl-β-D-glucosyl)-β-sitosterol; Structural formula: C 53 H 90 O 7 , and the specific structure is as follows:

[0053] .

[0054] Compound C5: Glycerol 1-eicosanoate 3-(4E,7E,10E-hexadecatrienoate), CAS No: 1415934-71-2, Name: Glycerol-1-eicosanoic acid-3-(4E,7E,10E-hexadecatrienoic acid), Structural formula: C 39 H 70 O 5 , and the specific structure is as follows:

[0055] .

[0056] Compound C6: 1,3-dihydroxylpropyl-(9Z,12Z)-octadeca-9,12-dienate, CAS No: 3443-82-1;

[0057] Chinese Name: Befunolol, 2-linolenoyl-rac-glycerol;

[0058] Structural formula: C 21 H 38 O 4 , and the specific structure is as follows:

[0059] .

[0060] In the present invention, the effective concentration of the Musella lasiocarpa extract (crude Musella lasiocarpa extract or refined components RC1-RC6) in the product is 1-100 μg / ml, specifically it can be 1 μg / ml, 10 μg / ml, 20 μg / ml, 30 μg / ml, 40 μg / ml, 50 μg / ml, 60 μg / ml, 70 μg / ml, 80 μg / ml, 90 μg / ml, 100 μg / ml.

[0061] In the present invention, the effective concentration of C1-C6 independently selects from 1-100 μg / ml, specifically it can be 1 μg / ml, 10 μg / ml, 20 μg / ml, 30 μg / ml, 40 μg / ml, 50 μg / ml, 60 μg / ml, 70 μg / ml, 80 μg / ml, 90 μg / ml, 100 μg / ml.

[0062] The present invention also provides a uric acid-lowering product, including at least one of the following C1-C6 compounds or the Musella lasiocarpa extract, and excipients:

[0063] C1 compound: 1,2',3',4',6'-penta-O-acetyl-3-O-(E)-p-coumaroyl sucrose;

[0064] C2 compound: 2',3',4',6'-tetra-O-acetyl-3-O-(E)-p-coumaroyl sucrose;

[0065] C3 compound: mumeose K;

[0066] C4 compound: daucosterol linoleate;

[0067] C5 compound: glycerol 1-eicosanoate 3-(4E,7E,10E-hexadecatrienoate);

[0068] C6 compound: 2-linolenoyl-rac-glycerol;

[0069] The C1-C6 compounds are extracted and separated from the Musella lasiocarpa extract.

[0070] The Musella lasiocarpa extract contains at least one of the C1-C6 compounds;

[0071] The Musella lasiocarpa extract is an ethanol extract of Musella lasiocarpa flowers and buds.

[0072] In the uric acid-lowering product of the present invention, the preparation method of the Musella lasiocarpa extract is as described above and will not be elaborated here.

[0073] In the present invention, the product includes health products, foods or drugs.

[0074] In the present invention, the product further includes excipients; the excipients include but are not limited to at least one of lubricants, surfactants, disintegrants, wetting agents, binders, fillers, excipients, absorption promoters, adsorption carriers and diluents.

[0075] The dosage form of the product of the present invention includes tablets, capsules, granules, liquid preparations, pills, powders, etc., and common dosage forms in the art are all applicable.

[0076] The present invention also provides a method for lowering uric acid, including: administering at least one of the Musella lasiocarpa extract or the C1-C6 compounds of the present invention. The present invention has no special limitation on the "administration" method, and a suitable method can be determined according to the conventional methods in the art in combination with the dosage form types as described above.

[0077] The present invention also provides a method for preventing and treating uric acid-lowering related diseases, including: administering at least one of the Musella lasiocarpa extract or the C1-C6 compounds of the present invention. Among them, the Musella lasiocarpa extract and the C1-C6 compounds are as described above. The uric acid-lowering related diseases include hyperuricemia and / or gout.

[0078] Research shows that the crude extract (i.e., the crude extract of Musella lasiocarpa), refined components (RC1-RC6), and compounds C1-C6 of the ethanol extract of Musella lasiocarpa flowers and flower buds all have strong inhibitory activities against xanthine oxidase, can effectively reduce uric acid levels, have the advantages of good uric acid-lowering effect and small side effects, and can be used for the preparation of uric acid-lowering products. BRIEF DESCRIPTION OF THE DRAWINGS

[0079] Figure 1 Shows the inhibition rates of the crude extract of Musella lasiocarpa and refined components RC1-RC6 against xanthine oxidase;

[0080] Figure 2 Shows the inhibition rates of the crude extract of Musella lasiocarpa and refined compounds C1-C6 against xanthine oxidase. DETAILED DESCRIPTION OF THE INVENTION

[0081] The present invention provides the application of Musella lasiocarpa extract in the preparation of uric acid-lowering products. Those skilled in the art can draw on the content of this article and appropriately modify the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and those related can obviously make changes or appropriate modifications and combinations to the methods and applications in this article without departing from the content, spirit, and scope of the present invention to implement and apply the technology of the present invention.

[0082] The test materials used in the present invention are all ordinary commercially available products and can be purchased in the market.

[0083] In a specific embodiment of the present invention, the crude extract of Musella lasiocarpa is prepared by the following method:

[0084] Take the flowers and flower buds of Musella lasiocarpa, extract them by cold soaking with 3 times the volume of 75% ethanol aqueous solution for 3 times, 24 hours each time, and concentrate the extract to dryness to obtain the crude extract of Musella lasiocarpa.

[0085] After preparing the crude extract of Musella lasiocarpa into a sample solution with the required concentration, measure the inhibition rate of xanthine oxidase.

[0086] In a specific embodiment of the present invention, the preparation method of the refined components RC1-RC6 of Musella lasiocarpa includes:

[0087] Take the flowers and flower buds of Musella lasiocarpa, extract them by cold soaking with 3 times the volume of 75% ethanol aqueous solution for 3 times, 24 hours each time, and concentrate the extract to dryness to obtain the crude extract of Musella lasiocarpa;

[0088] Load the crude extract of Musella lasiocarpa onto an MCI column and elute it successively with water, 20% methanol solution, 40% methanol solution, 60% methanol solution, 80% methanol solution, and 100% methanol solution to obtain the refined components RC1 - RC6 of Musella lasiocarpa respectively.

[0089] During the elution, each gradient is eluted with 3 column volumes.

[0090] Specifically, RC1 is the fraction eluted with water after MCI chromatography separation;

[0091] RC2 is the fraction eluted with 20% methanol aqueous solution after MCI chromatography separation;

[0092] RC3 is the fraction eluted with 40% methanol aqueous solution after MCI chromatography separation;

[0093] RC4 is the fraction eluted with 60% methanol aqueous solution after MCI chromatography separation;

[0094] RC5 is the fraction eluted with 80% methanol aqueous solution after MCI chromatography separation;

[0095] RC6 is the fraction eluted with 100% methanol after MCI chromatography separation.

[0096] After preparing the refined components RC1 - RC6 of Musella lasiocarpa into sample solutions with the required concentrations, measure the xanthine oxidase inhibition rate.

[0097] The present invention will be further elaborated below in conjunction with the embodiments:

[0098] Example 1

[0099] (I) Measure the xanthine oxidase inhibition rate of the sample

[0100] 1. Solution preparation:

[0101] (1) 7× Phosphate buffer (pH 7.5).

[0102] (2) 1.5 mM Xanthine solution: Weigh an appropriate amount of xanthine powder precisely and prepare a solution with 7× phosphate buffer.

[0103] (3) 0.04 U / mL Xanthine oxidase (XO) solution: Weigh xanthine oxidase precisely, dissolve it in 7× phosphate buffer, and prepare an enzyme solution with a concentration of 0.04 U / mL. The working concentration is 10 mU.

[0104] (4) Allopurinol: Weigh an appropriate amount of allopurinol powder precisely, prepare a stock solution with DMSO at a concentration of 4 mg / mL, and prepare the corresponding sub - stock solution with 7× phosphate buffer when needed for the experiment.

[0105] (5)Samples: Prepare the following samples according to the method described above: Musella lasiocarpa crude extract, refined components RC1 - RC6, and compounds C1 - C6. Weigh an appropriate amount of the samples precisely, and prepare sample solutions with corresponding concentrations using 7× phosphate buffer when required for the experiment.

[0106] 2. Prepare a 96 - well plate, add 50 μL of 7× phosphate buffer, 50 μL of 0.04 U / mL xanthine oxidase (XO) solution, and 50 μL of the sample solution respectively, and incubate at 25 °C for 15 min.

[0107] 3. Add 50 μL of 1.5 mM xanthine solution to start the reaction, and incubate at 25 °C for 8 min.

[0108] 4. Measure the absorbance (A) value at 295 nm.

[0109] 5. For the sample group, it is As. Use buffer instead of the sample as the blank control (Ab), phosphate buffer instead of xanthine as the negative control (Ac), and allopurinol instead of the sample as the positive control.

[0110] 6. Xanthine oxidase inhibition rate (%) = (Ab−(As−Ac)) / Ab × 100%.

[0111] (II) Anti - xanthine oxidase efficacy of Musella lasiocarpa crude extract and refined components

[0112] Table 1 Xanthine oxidase inhibition rates of Musella lasiocarpa crude extract and refined components

[0113] Group Xanthine Oxidase Inhibition Rate (%) SD Allopurinol - 100 μg / ml 85.50 0.71 Allopurinol - 10 μg / ml 81.50 0.71 Allopurinol - 1 μg / ml 81.50 0.71 Crude Extract of Musella lasiocarpa - 100 μg / ml 46.50 0.71 Crude Extract of Musella lasiocarpa - 10 μg / ml 48.00 1.41 Crude Extract of Musella lasiocarpa - 1 μg / ml 77.50 0.71 RC1 - 100 μg / ml 42.00 12.73 RC1 - 10 μg / ml 41.50 0.71 RC1 - 1 μg / ml 40.50 0.71 RC2 - 100 μg / ml 49.00 1.41 RC2 - 10 μg / ml 42.50 0.71 RC2 - 1 μg / ml 43.50 0.71 RC3 - 100 μg / ml 31.50 6.36 RC3 - 10 μg / ml 43.00 1.41 RC3 - 1 μg / ml 44.50 0.71 RC4 - 100 μg / ml 29.00 1.41 RC4 - 10 μg / ml 45.50 2.12 RC4 - 1 μg / ml 47.00 1.41 RC5 - 100 μg / ml 7.00 1.41 RC5 - 10 μg / ml 43.50 0.71 RC5 - 1 μg / ml 48.00 1.41 RC6 - 100 μg / ml 38.00 2.83 RC6 - 10 μg / ml 48.50 0.71 RC6 - 1 μg / ml 50.00 1.41

[0114] Summary: The positive standard allopurinol with 3 concentration gradients shows good xanthine oxidase activity inhibition rate, indicating the success of the experimental system. The Musella lasiocarpa crude extract and the six refined components RC1 - RC6 of Musella lasiocarpa all show good anti - xanthine oxidase activity, indicating that the crude extract can effectively inhibit the activity of xanthine oxidase, thereby reducing the synthesis of uric acid, lowering the blood uric acid level, and can be used in the preparation of products for reducing uric acid.

[0115] (III) Anti - xanthine oxidase efficacy of Musella lasiocarpa crude extract and refined compounds

[0116] Table 2 Xanthine oxidase inhibition rates of Musella lasiocarpa crude extract and refined compounds

[0117] Group Xanthine Oxidase Inhibition Rate (%) SD Allopurinol - 100 μg / ml 85.50 0.71 Allopurinol - 10 μg / ml 81.50 0.71 Allopurinol - 1 μg / ml 81.50 0.71 Crude Extract of Musella lasiocarpa - 100 μg / ml 46.50 0.71 Crude Extract of Musella lasiocarpa - 10 μg / ml 48.00 1.41 Crude Extract of Musella lasiocarpa - 1 μg / ml 77.50 0.71 C1 - 100 μg / ml -6.50 2.12 C1 - 10 μg / ml 46.50 0.71 C1 - 1 μg / ml 54.50 7.78 C2 - 100 μg / ml 52.50 0.71 C2 - 10 μg / ml 51.00 2.83 C2 - 1 μg / ml 50.50 0.71 C3 - 100 μg / ml -46.50 2.12 C3 - 10 μg / ml 27.50 3.54 C3 - 1 μg / ml 68.50 9.19 C4 - 100 μg / ml 1.00 1.41 C4 - 10 μg / ml 39.50 0.71 C4 - 1 μg / ml 65.50 2.12 C5 - 100 μg / ml 44.50 0.71 C5 - 10 μg / ml 41.00 1.41 C5 - 1 μg / ml 72.50 0.71 C6 - 100 μg / ml 42.50 0.71 C6 - 10 μg / ml 43.50 0.71 C6 - 1 μg / ml 74.50 0.71

[0118] Summary: The use of allopurinol with three concentration gradients showed good inhibitory rates of xanthine oxidase activity, indicating the success of the experimental system. The crude extract of Musella lasiocarpa and six refined compounds C1 - C6 of Musella lasiocarpa all showed good anti-xanthine oxidase activity at low concentrations, with strong anti-xanthine oxidase efficacy. Among them, the effects of C5 - C6 in the refined compounds were better.

[0119] The above are only the preferred embodiments of the present invention. It should be noted that for those of ordinary skill in the art, without departing from the principle of the present invention, several improvements and refinements can be made, and these improvements and refinements should also be regarded as the protection scope of the present invention.

Claims

1. Application of C6 compound as the sole active ingredient in the preparation of uric acid-lowering products: C6 compound: 2-linolenoyl-rac-glycerol, its structural formula is as follows: 。 2. The use according to claim 1, characterized in that: The uric acid-lowering products include drugs for preventing and treating diseases related to high uric acid; The hyperuric acid-related diseases include hyperuricemia and / or gout.

3. The use according to claim 1 or 2, characterized in that: The C6 compound is extracted and separated from the extract of the Herba Lycoris Radiatae.

4. Application of C6 compound as the sole active ingredient in the preparation of xanthine oxidase inhibitors: C6 compound: 2-linolenoyl-rac-glycerol, its structural formula is as follows: 。 5. The use according to claim 4, characterized in that: The C6 compound is extracted and separated from the extract of the Herba Lycoris Radiatae.

6. The use according to claim 1 or 4, characterized in that: The effective concentration of the C6 compound is selected from 1 to 100 μg / ml.

7. A uric acid lowering product, characterized in that: Composed of C6 compounds and excipients: C6 compound: 2-linolenoyl-rac-glycerol.

8. The uric acid lowering product according to claim 7, characterized in that: The product described is a drug.

9. The uric acid lowering product according to claim 7, characterized in that: The auxiliary materials include at least one of lubricants, surfactants, disintegrants, wetting agents, adhesives, fillers, excipients, absorption promoters, adsorption carriers and diluents.

10. The uric acid lowering product according to any one of claims 7 to 9, characterized in that: The dosage form of the product includes tablets, capsules, granules, liquid preparations, pills or powders.

Images